I am so honored to be a 2024 AACR Research Minority in Cancer Research Scholar awardee - Kimberly S. Meza
Wafik S. El-Deiry, MD, PhD, FACP NCI Disparities

#AACR24 #Cancer #Cancer Research #HealthDisparities #OncoDaily #Oncology

oncodaily.com/49123.html

Biliary tract cancers therapeutic studies summarized by Erman Akkus at AACR

#AACR24 #BiliaryTractCancer #Chemotherapy #Cholangiocarcinoma #OncoDaily #Oncology #CancerResearch #SanDiego

oncodaily.com/49597.html

#AACR24 ⁦AACR⁩ - Selected Highlights of #clinicaltrial data (in my opinion)- focus on early clinical drug development of single agent therapy for #cancer ⁦VuMedi⁩ ⁦Vivek Subbiah, MD⁩ ⁦Sumanta K. Pal, MD, FASCO⁩ ⁦Neeraj Agarwal, MD, FASCO⁩ vumedi.com/video/clinical…

Honored to be the recipient of the 2024 AACR Scholar-in-Training Award 🏆 I never thought I’d give a talk at the world’s biggest cancer research meeting, let alone be recognized for my work in the field. To those who walked this fulfilling journey with me, thank you! 🥂 #AACR24

Reunited with amazing #WomenInSTEM who are leaders in diversifying #CancerResearch … thank you #aacr24 for giving me extra determination to #MakeADifference

It was great being part of #AACR24 in San Diego! The conference showcased pioneering science. This was also the 2nd year I received the Scholar-in-Training award which was instrumental in facilitating my attendance - grateful for the recognition and opportunity to attend.

ATM Inhibitor Plus Radiotherapy Shows Manageable Safety Profile, Preliminary Efficacy in Phase I Trial

Learn more ➡️ bit.ly/442BhRl
AACR Jonathan Yang Memorial Sloan Kettering Cancer Center
#AACR24 #HeadAndNeckCancer #HNC #Glioblastoma #RadOncNews #CancerTreatment

Beyond Immune Checkpoint Inhibition: Novel Immunotherapy Strategies — Researchers presented the latest clinical trial results during this plenary session at #AACR24 . Read a recap in AACR Annual Meeting News: bit.ly/3UsRPio

Should we consider them 2nd generation PARP inhibitors or a completely NEW class of drugs? - Vivek Subbiah, MD

oncodaily.com/49282.html

#oncodaily #oncology #cancer #PARP1 #PARPinhibitors #AACR24 #drugdevelopment #precisionmedicine #cancer research #biotechnology

⭐️Yes! The future IS now! “AI at the Interface: Accelerating Evidence Generation, Advancing Disparities Research, and Improving Trial Design” — Read a recap of this #AACR24 plenary session in AACR Annual Meeting News: bit.ly/4aROQ8q
Anant Madabhushi Thomas Clozel Mia Levy, MD, PhD

Pass by! Section 13 board 18.
#AACR24 #AACRglobalscholars

Nothing like a wonderful surprise, in person get together of two OHSU Knight Cancer Institute #advocates during #AACR24 . Thanks to Mary Pat for stopping by my AACR Scientist↔Survivor Program post session along with so many other advocates and researchers!

Check out our recent presentation at the AACR Annual Meeting 2024.
bit.ly/3LLVzH1

$MBRX AACR #AACR24 #Oncology #AcuteMyeloidLeukemia #STSLungMets

The AACR honored U.K. researchers for their work to increase testing for Lynch syndrome. Read more about their work and why this testing is important for people with endometrial cancer in Cancer Today. bit.ly/4aVQhCS #AACR24 Emma Crosbie

Fantastic presentation #AACR24 by Shawn Lee from our lab on the ability of CAF-derived DKK1 to suppress NK cells in breast cancer. Shawn is also the recipient of the AACR student in training award! WUSTL Immunology WashU Ortho Research Siteman Cancer Center

A pan-cancer analysis of the microbiome in metastatic cancer - Vivek Subbiah, MD
Antonio Carlos Cell Press

#AACR24 #Cancer #FDA #Fusobacterium #MetastaticCancer #NSCLC #OncoDaily #Oncology #Cancer Research

oncodaily.com/47587.html

In my latest post I analyze emerging IL-2 variant data from #AACR24 , including promising monotherapy efficacy from Synthekine & Medicenna Tx. Despite past failures, this modality still holds therapeutic potential if designs are optimized.

Link in comments for the full analysis

Honored to be in the list of top influencers #AACR24 by LARVOL 😊

Did you catch us at #AACR24 ? If not, learn how iPair BCR/TCR sequencing allows you to validate tumor neoantigen peptides with patient-derived PBMCs, and accelerate your cancer vaccine development.

hubs.li/Q02sYGct0

#CancerResearch #ImmuneProfiling #NGS

The Arima team had an amazing time at #AACR24 ! Big thanks to all who joined our talk, visited our booth, and stopped by our poster session. It was inspiring to connect in person with so many scientists in the #cancerresearch community. 📷 Swipe through for some highlights! AACR